Search clinical trials for: fluzoparib camrelizumab

Total 486 results

wang shusen

Recruiting

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Fudan University

Recruiting

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Ruijin Hospital

Recruiting

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)

Sarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

China
Jun Guo

Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Melanoma
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Food-Effect and Metabolism Study in Healthy Subjects

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.
307 Hospital of PLA; Peking University Cancer Hospital & Institute

Completed

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Ying Lin

Recruiting

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation (IMPARP)

Her-2 Negative Breast Cancer | HRR Gene Mutation

China
Atridia Pty Ltd.

Completed

A Trial of SHR3162 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Atridia Pty Ltd.

Completed

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

Solid Tumors | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Small Cell Lung Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Esophageal Cancer

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Tongji Hospital
First Affiliated Hospital Xi'an Jiaotong University; Wuhan Union Hospital,... and other collaborators

Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Xiaohua Wu MD

Not yet recruiting

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Ovarian Cancer

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Fujian Medical University Union Hospital

Recruiting

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Radiotherapy | Immunotherapy | Esophageal Neoplasm

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

HNSCC

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Peking University

Not yet recruiting

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Esophageal Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (ESCC)

Esophageal Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Oligometastasis | Radiotherapy

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Henan Provincial People's Hospital

Not yet recruiting

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study (NSCLC)

Nsclc
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NSCLC)

NSCLC
Sun Yat-sen University

Recruiting

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Paranasal Sinus Cancer | Induction Chemotherapy | Camrelizumab | Nasal Cavity Cancer | Intensity Modulated Radiotherapy | Concurrent Chemotherapy

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Huashan Hospital
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.

Recruiting

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer (CAN-RESPOND)

Endometrial Cancer
Jiangxi Provincial Cancer Hospital

Recruiting

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Triple-Negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China

Search clinical trials for: fluzoparib camrelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations